Open Access

Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: A case report

  • Authors:
    • Ken Sasaki
    • Yasuto Uchikado
    • Itaru Omoto
    • Masahiko Amatatsu
    • Koichi Megumi
    • Hiroshi Okumura
    • Kosei Maemura
    • Shoji Natsugoe
  • View Affiliations

  • Published online on: February 13, 2018     https://doi.org/10.3892/mco.2018.1572
  • Copyright: © Sasaki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Standard treatment strategies have not yet been established for primary malignant melanoma of the esophagus (PMME), and far much less for recurrent disease. There are no reports of anti- programmed death-1 antibody treatment of recurrent PMME. A 60-year‑old Japanese man was diagnosed with a primary malignant melanoma in the lower esophagus. The patient underwent mediastinoscope-assisted subtotal esophagectomy, and two nodal involvements were detected in the lymph nodes (LN)s along the left gastric artery. Paclitaxel and oral fluoropyrimidine were administered for 2 months as adjuvant treatment based on results of a histoculture drug response assay. Computed tomography at 8 months after following surgery revealed LN metastasis around the celiac axis. The serum level of the tumor marker 5-S-cysteinyldopa was elevated aberrantly. Although treatment with dacarbazine and interferon-β was initiated, metastatic disease progressed. Therefore, we started anti-programmed death-1 antibody therapy. Following 8 treatment courses, the patient demonstrated a partial response; however, after following 4 more treatment courses, the patient demonstrated progressive disease. Next, hypofractionated radiotherapy was targeted at the metastatic LN and resulted in a partial response. Then, ipilimumab, an anti-cytotoxic T-lymphocyte associated antigen 4, was administered at a dose of 3 mg/kg. After the initial administration of ipilimumab, grade 3 peripheral neuropathy was recognized; thereafter, ipilimumab was not administered. A total of 18 months after following treatment for metastatic LNs, the LN decreased in size, and there were no other signs of metastasis to other organs. The patient then underwent laparoscopic celiac axis lymphadenectomy. Pathological examination of the surgical specimens identified no viable melanoma cells. A total of 8 months after following surgery, he is free from evidence of disease recurrence. This is the first reported case of recurrent PMME successfully treated with multidisciplinary therapy including anti-programmed death-1 antibody therapy, radiotherapy and laparoscopic lymphadenectomy.

Related Articles

Journal Cover

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sasaki, K., Uchikado, Y., Omoto, I., Amatatsu, M., Megumi, K., Okumura, H. ... Natsugoe, S. (1899). Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: A case report. Molecular and Clinical Oncology, 0, 0-0. https://doi.org/10.3892/mco.2018.1572
MLA
Sasaki, K., Uchikado, Y., Omoto, I., Amatatsu, M., Megumi, K., Okumura, H., Maemura, K., Natsugoe, S."Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: A case report". Molecular and Clinical Oncology 0.0 (1899): 0-0.
Chicago
Sasaki, K., Uchikado, Y., Omoto, I., Amatatsu, M., Megumi, K., Okumura, H., Maemura, K., Natsugoe, S."Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: A case report". Molecular and Clinical Oncology 0, no. 0 (1899): 0-0. https://doi.org/10.3892/mco.2018.1572